Credit Suisse Reiterates Neutral Rating for Achillion Pharmaceuticals (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN)‘s stock had its “neutral” rating reissued by Credit Suisse in a research note issued on Thursday. They currently have a $10.00 price objective on the stock, up from their previous price objective of $4.00. Credit Suisse’s price objective would indicate a potential upside of 2.04% from the stock’s previous close.
In other Achillion Pharmaceuticals news, major shareholder Ra Capital Management, Llc unloaded 4,235,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $9.53, for a total value of $40,359,550.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 3.01% on Thursday, hitting $9.495. 1,776,554 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $10.18. The stock has a 50-day moving average of $7.49 and a 200-day moving average of $4.73. The company’s market cap is $928.5 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ACHN. Analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. They now have a $17.00 price target on the stock, up previously from $6.00. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. Finally, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. They set an “outperform” rating and a $12.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $9.50.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.